Recent advances in our understanding of hypereosinophilia have related particularly to the definition of criteria for distinguishing between eosinophilic leukemia and the 'idiopathic' hypereosinophilic syndromes. In this article, leukemogenic mechanisms have been identified in a number of subtypes of eosinophilic leukemia, and the role of clones of T lymphocytes in the causation of otherwise unexplained eosinophilia has been further elucidated. The roles of various therapeutic modalities-including cytotoxic chemotherapy, interferon and bone marrow transplantation-in eosinophilic leukemia and in the idiopathic hypereosinophilic syndrome also have been further defined.